Gilead to buy Arcellx for $7.8B to secure cancer therapy anito-cel
What's the deal? Gilead SciencesDealroom has a profile for this one. Try Dealroom → has agreed to acquire US biotech Arcellx in a deal valued at about $7.8 billion, securing full control of its experimental cancer therapy anito-cel.
The transaction, expected to close in the second quarter of 2026, gives Gilead the stake in Arcellx that it does not already own.
Anito-cel is a CAR-T cell therapy in development for multiple myeloma, a blood cancer. Gilead and Arcellx previously partnered on the treatment through Gilead’s Kite subsidiary, which held a minority stake in Arcellx.
Why now? The acquisition deepens Gilead’s push into oncology, a key growth area beyond its HIV and antiviral business. Full ownership of anito-cel allows it to capture more upside if the therapy wins approval and market share.
Competition in CAR-T therapies is intensifying, with Bristol Myers SquibbDealroom has a profile for this one. Try Dealroom → and Johnson & JohnsonDealroom has a profile for this one. Try Dealroom → already marketing approved products. Owning the asset outright gives Gilead greater control over development, manufacturing, and commercial strategy.
What could go wrong? Anito-cel remains in clinical development and lacks full regulatory approval. Clinical setbacks or safety concerns could weaken the deal’s logic.
CAR-T therapies are complex and expensive to make, and pricing pressure is rising. Even with approval, reimbursement hurdles and competition could limit returns.
Large biotech acquisitions carry integration risks. Gilead must align operations and timelines to realise the therapy’s potential.
The signal: The $7.8 billion deal highlights big pharma’s appetite for late-stage biotech assets with blockbuster potential. As pipelines thin, acquisitions remain a core growth strategy.
It also shows sustained belief in cell therapy despite high costs and operational hurdles. For venture-backed biotech, deep-pocketed buyers remain the most likely exit.
Sources:
Arcellx
Gilead Sciences
Reuters
Business Wire
CNBC
Morningstar
J.V.
